FDA accepts Sunlight Pharma’s dry eye therapy
The FDA has actually authorized Cequa for the treatment of dry eye illness, Sun Drug Industries stated in a news release.
Cequa (cyclosporine sensory solution 0.09%), is the highest possible FDA-approved focus of cyclosporine A and the very first to integrate nanomicellar modern technology, and is indicated to enhance tear production in the eyes, the press release said.
“Dry eye illness stands for an area of a high unmet clinical need, with a considerable number of clients that are currently without treatment,” Abhay Gandhi, Sunlight Pharma North America Chief Executive Officer, said in the release. “The U.S. FDA authorization of Cequa signifies a long-awaited completely dry eye therapy choice as well as is a crucial landmark in the advancement of Sun’s Ophthalmics business. Cequa, with its exceptional nanomicellar formula for a tried and tested completely dry eye drug, supplies a lipophilic molecule in a clear solution form.”